clinic arizona, Phoenix, aZ cardiovascular disease (cVD) is a leading cause of post-liver transplant death, and variable care patterns may affect outcomes. We aimed to describe epidemiology and outcomes of inpatient cVD care across US hospitals. Using a merged data set from the 2002-2011 nationwide inpatient Sample and the american Hospital association annual Survey, we evaluated liver transplant patients admitted primarily with myocardial infarction (Mi), stroke (cerebrovascular accident [cVa]), congestive heart failure (cHF), dysrhythmias, cardiac arrest (ca), or malignant hypertension. Patient-level data include demographics, charlson comorbidity index, and cVD diagnoses. Facility-level variables included ownership status, payer-mix, hospital resources, teaching status, and physician/nursing-to-bed ratios. We used generalized estimating equations to evaluate patient-and hospital-level factors associated with mortality. there were 4763 hospitalizations that occurred in 153 facilities (transplant hospitals, n = 80). cVD hospitalizations increased overall by 115% over the decade (P < 0.01). cVa and Mi declined over time (both P < 0.05), but cHF and dysrhythmia grew significantly (both P < 0.03); a total of 19% of hospitalizations were for multiple cVD diagnoses. transplant hospitals had lower comorbidity patients (P < 0.001) and greater resource intensity including presence of cardiac intensive care unit, interventional radiology, operating rooms, teaching status, and nursing density (all P < 0.01). transplant and nontransplant hospitals had similar unadjusted mortality (overall, 3.9%, P = 0.55; by diagnosis, all P > 0.07). transplant hospitals had significantly longer overall length of stay, higher total costs, and more high-cost hospitalizations (all P < 0.05). after risk adjustment, transplant hospitals were associated with higher mortality and high-cost hospitalizations. in conclusion, cVD after liver transplant is evolving and responsible for growing rates of inpatient care. transplant hospitals are associated with poor outcomes, even after risk adjustment for patient and hospital characteristics, which may be attributable to selective referral of certain patient phenotypes but could also be related to differences in quality of care. Further study is warranted.
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From a population perspective, liver transplant recipients are at significant risk for morbidity and mortality from cardiovascular disease (CVD). CVD is a leading cause of longterm morbidity and mortality after transplant. (1) (2) (3) (4) (5) (6) This is likely related to the shifting epidemiology of pretransplant risk factors in modern liver transplantation and immunosuppression-related acceleration of atherosclerosis. Recipients are transplanted at older age and with higher rates of traditional atherosclerosis risk factors. (1) (2) (3) (4) (5) The incidence of nonalcoholic fatty liver disease is rising, and it is independently associated with CVD. (7) (8) (9) (10) (11) (12) (13) Posttransplant management obligates recipients to use calcineurin inhibitors and mammalian target of rapamycin inhibitors that are associated with cardiovascular (CV) risk factor exacerbation. (14) (15) (16) (17) Careful transplant candidate selection is an opportunity to minimize CV events in the posttransplant population through thorough evaluation. Despite recognition of population risk factors and careful risk mitigation in individual candidate selection, multiple reports indicate
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that CVD is a leading driver of post-liver transplant mortality and health care utilization. (1) (2) (3) (4) (5) (6) Once a CV event occurs in a liver transplant patient, there are sparse data on how patient-level and health system-level factors affect outcomes in the inpatient setting. Liver transplant patients presenting with CV events are high risk and require resource-intense care. Current evidence indicates that variation in hospital practices may negatively affect outcomes; hospitals vary substantially in myocardial infarction (MI) mortality, practice patterns, and compliance with CV quality measures. (18) (19) (20) (21) (22) (23) (24) (25) (26) If faced with an acute CV event in a liver transplant patient, most clinicians would agree that transplant facilities are well resourced to provide the best care, based on the needs for multidisciplinary coordinated care, comprehensive cardiology services, specialized imaging and therapeutic capabilities, and other facilities to address deterioration of liver function, threatened allografts, immunosuppression, and numerous other queries. However, in kidney transplant patients, an analogous population, nontransplant hospitals have demonstrated similar outcomes as transplant hospitals in managing CV events. (27) This generates important questions germane to the longterm management of liver transplant patients: Do liver transplant centers provide better care than nontransplant hospitals for CV events, and how does this care differ? These questions have important implications for liver transplant providers, transplant recipients, and the design of CV care management paradigms in this unique population.
The rationale for this study was to evaluate patterns of care and outcomes from CV events in liver transplant patients and to identify whether hospital type and resource intensity affect these outcomes. Using a novel administrative data set, we adapted the Donabedian framework of health care quality to evaluate patient risk factors and hospital structural factors associated with mortality and high-cost care when liver transplant patients are admitted with CV events to acute care hospitals. (28) 
Patients and Methods

CoNCEptuAL MoDEL oF Cv EvENt outCoMES iN LivER tRANSpLANt pAtiENtS
Using the Donabedian model of measuring health care quality, the prerequisites to understanding hospital differences in mortality within this population are measuring and accounting for differences in the following:
1. Patient populations. 2. Key facility structural characteristics, which include organizational elements, facilities and services, as well as ownership and financial status. 3. Processes of care that appropriately use facilities and services to deliver treatment ( Fig. 1 ).
Previous studies have demonstrated how facilitylevel factors affect surgical outcomes across hospitals (29) (30) (31) (32) as well as CVD outcomes. (21, 25, 26, (33) (34) (35) We hypothesized that after accounting for patient differences, hospitals with established transplant programs would have better outcomes compared with facilities without transplant programs. Dedicated specialty care from cardiology and intensive care services coupled with proven protocols and processes and an overwhelming "organizational awareness" of transplant-related issues allows transplant facilities to offer efficient and superior care to post-liver transplant patients experiencing major CV events, thereby improving outcomes and lowering overall costs. We constructed our statistical models for mortality hierarchically by taking into account that patients with different clinical characteristics were clustered within hospitals. This assumption was predicated on the theory that across the population, mortality was attributable to both clinical comorbidities and unique hospital effects, which were mediated by the presence of resources and processes of care that manipulate those resources. We applied this conceptual framework to model high-cost hospitalizations as well.
DAtA SouRCES
We created a unique data set to capture 2002-2011 hospital admissions for liver transplant patients admitted with CVD with hospital-specific resource data. We used the Nationwide Inpatient Sample (NIS), a data set available through the Healthcare Cost and Utilization Project (HCUP). The NIS is a 20% national administrative data sample of all US hospital discharges and contains demographic, diagnosis, and therapeutic information within a given hospitalization episode without patient identifiers. Diagnosis and therapeutic interventions are classified based on 9th International Classification of Diseases codes. We merged hospitalization episode-based NIS data with hospital structural data from the American Hospital Association (AHA) Annual Survey of Hospitals using the Medicare provider identification number. The AHA survey contains 1000 self-reported data elements on organizational structure, facilities and services, payer mix, and financial performance from 6500 hospitals.
This study sample included patients with liver transplant status (V42.70) and at least 1 primary or secondary CV diagnosis. CV diagnoses included at least 1 of the following: MI (410.x), congestive heart failure (CHF; 428.x), dysrhythmia (427.x), cerebrovascular accident (CVA; 436.x, 437.1, 997.x), malignant hypertension (HTN; 402.x), and cardiac arrest (427.5, 997.1). Hospitalizations where liver transplant procedures occurred (V50.5) were excluded. Risk adjustment based on clinical characteristics was derived from the Charlson comorbidity score. Cost data were obtained from individual hospital cost-to-charge ratios provided by the Centers for Medicare and Medicaid Services, as described previously. (36) The hospital structural variables were obtained from the AHA 2009 survey data. Hence, the hospitals that were in both HCUP and NIS databases were included in the analysis. After combining AHA and NIS data, there were 31,526 hospital admissions (from 5033 hospitals) with a history of liver transplant. Of those hospital admissions, 7046 (22.3%) encounters at 1004 hospitals had at least 1 CV diagnosis. From the 1004 hospitals, we further excluded those with less than 10 admissions over the study period, and the ultimate sample size of the final analytical set was 4763 admissions at 153 hospitals.
vARiABLES
We analyzed a variety of outcomes including patient mortality and total hospitalization cost using an inflation-adjusted approach by applying the cost-to-charge ratio and GDP (gross domestic product) to the total hospital charge. The inflation was adjusted using year 2011 as a reference. Furthermore, length of stay (LOS) was examined. Independent patient characteristics included year of admission, age at admission, sex, race, primary payer, median household income, transfer-in indicator, type of admission, in-hospital death, in-hospital dialysis, CV diagnosis, and weighted modified Charlson-Deyo score (MI, CHF, and cardiac arrest excluded). Hospital characteristics included transplant hospital, ownership/control code, medical/surgical intensive care, cardiac intensive care, health maintenance organization (HMO)/preferred provider organization (PPO), cardiology/cardiac surgery services, freestanding/satellite emergency department, multislice computed tomography (>64-slice) hospital, interventional radiology therapy, hospital unit inpatient days, proportion of hospital unit Medicare discharges, proportion of hospital unit Medicaid discharges, number of operating rooms, total surgical volume, surgical intensity, hospital total expenses, electronic health records, outcomes. This figure represents the determinants of outcomes from acute CV events requiring inpatient hospitalization, based on the Donabedian model of health care quality. Conceptually, the "hospital effect" on a particular outcome is an amalgamation of the effect of facility resources, capacity, finances, and organizational structure, which in turn provide the context for developing processes of care and care pathways. For liver transplant patients who have an acute CV event, multiple factors contribute to the risk of mortality and high-cost care, which should be considered in modeling outcomes to improve care delivery.
Original article | 1401 physician full-time equivalent (FTE)/bed, resident or trainee/bed, and nurse FTE/bed.
StAtiStiCAL ANALYSiS
Comparison Between Hospitals
For the comparison between transplant and nontransplant hospitals' patient and facility characteristics, the 2-sample test, Wilcoxon rank sum test, chi-square test, and Fisher's exact test were used.
Determinants of Mortality and High-Cost Hospitalizations
To identify the hospital structural variables from the AHA survey, we used the Classification and Regression Tree (CART) method to select the candidate variables that were potentially associated with an outcome and transplant hospital status. (37) CART is a nonparametric approach that optimally classifies observations into mutually exclusive groups. The procedure starts with identifying a single hospital variable that can strongly divide observations into 2 groups. Within each group, the observations are further divided based on the other variables. The procedure is repeated for each subgroup until the prespecified stopping rules are met. The hospital structural variables that formed the trees were considered in the model selection procedure.
We constructed generalized estimating equations (GEEs) to evaluate the factors associated with outcomes. (38) The outcomes of interest were tested in separate models and included mortality and high-cost hospitalization. High-cost hospitalization was defined as being in the highest quartile of hospital episode costs across all modeled hospitalizations. Because the admissions were nested within hospitals and the outcomes within the same hospital may be correlated, this clustering effect was accounted for by the working correlation in the GEE. Population average estimates were used to construct the odds ratio (OR) and the 95% confidence interval (CI) for individual covariates. The backward elimination technique was used to select the best model, and the variables with P value < 0.4 were retained in the model.
We used publicly available data sources without patient identifiers, and the project was exempt from institutional review board approval. The analysis was conducted in SAS, version 9.4 (SAS Institute, Cary, NC) and in R, version 3.1.3 (R Foundation for Statistical Computing, Vienna, Austria). All tests were 2-sided, and a P value < 0.05 was considered statistically significant.
results
As enumerated in the Patients and Methods section, the final analytic data set included 4763 hospitalization episodes across 153 hospitals; 24% of hospitalization episodes occurred in nontransplant facilities (n = 1144 episodes over 73 hospitals), and 76% of episodes were in transplant facilities (n = 3619 episodes over 80 hospitals). As shown in Fig. 2 , the principal CV diagnoses prompting inpatient care changed over time. Although not mutually exclusive, CHF (43.8% of episodes) and dysrhythmias (60.9% of episodes) accounted for the greatest proportion of CV diagnoses by 2011. By 2011, stroke admissions decreased 3-fold over the study period, and MI admissions decreased by nearly half from 9.5% to 5.5%. Table 1 indicates the number of admissions in both types of facilities more than doubled over time. Table 1 also displays patient and hospital characteristics of liver transplant recipients admitted for CV events stratified by transplant hospital status. There were significant patient differences between transplant and nontransplant facilities. Compared with transplant facilities, nontransplant facilities admitted significantly older patients overall, a greater proportion of females, but had similar proportions of nonwhite In the first decade of the 21st century, there has been a significant change in the types of CV events that prompt inpatient admission in the post-liver transplant population. Over time, there has been a significant increase in the admissions for CHF and dysrhythmias. There has also been a significant reduction in the number of acute MI admissions, as well as significantly lower admissions for stroke, cardiac arrest, and malignant HTN over this period. Each hospitalization episode could carry more than 1 CV diagnosis, ie, these diagnoses are not mutually exclusive.
patients. Insurance and socioeconomic status also differed between groups. Nontransplant hospitals admitted more Medicare patients, and transplant facilities had significantly more Medicaid and commercially insured patients. Nontransplant hospitals had significantly more patients from areas with higher household incomes compared with transplant hospitals.
The distribution of primary CV diagnoses differed between the 2 types of facilities. Nontransplant hospitals had substantially lower proportions of stroke and cardiac arrest admissions compared with their transplant counterparts. However, transplant facilities admitted patients with more complex CV conditions, as defined by the number of CV diagnoses present at admission, and substantially more hospitalizations occurred there as a result of transfer from another acute care hospital (13.1% versus 5.5%). Most admissions in the cohort were classified as emergent/ urgent, particularly in nontransplant hospitals (90.7%). Comorbidities differed in the patients admitted to each hospital type. Patients in nontransplant facilities were classified with higher Charlson scores compared with transplant facilities. However, primary CV diagnosis of MI, CHF, and cardiac arrest were excluded. However, nontransplant facility admissions had significantly higher rates of diabetes (nearly 40% of total cohort) and dyslipidemia.
Overall, 22.4% of CV hospitalizations included invasive CV procedures, including cardiac catheterization and cardiac surgery. The distribution of invasive CV therapies also differed between the hospitals. Transplant facilities had higher rates of invasive therapy (transplant 23.4% versus nontransplant 19.6%). Cardiac surgery including coronary artery bypass graft (CABG), valve replacement/repair, or other cardiac surgery was significantly more prevalent in transplant facilities, whereas diagnostic and therapeutic catheterization rates were similar between hospital types.
Transplant and nontransplant hospital characteristics differed significantly. More nontransplant hospitals were considered nongovernmental nonprofit and investor-owned for-profit organizations. Payer mix differed, with transplant hospitals having more frequent designation as HMO or PPO facilities, less overall Medicare discharges, and more Medicaid discharges. Transplant hospitals also had a significantly greater proportion of hospitals with greater-thanmedian total annual expenses. Transplant hospitals had more technological resources and higher staffing levels than nontransplant hospitals.
Overall unadjusted mortality was 3.9% for the entire cohort and was slightly higher in the transplant hospital group without reaching statistical significance. By diagnosis, transplant and nontransplant hospitals had similar mortality rates (Table 2) . However, transplant hospitals had significantly longer overall LOS, higher total costs, and more high-cost hospitalizations (Table 1) . Figure 3 shows the vast differences in average per-episode unadjusted cost by hospital across all CV diagnoses, which varied by 5-fold. Table 2 describes cost differences by primary CV diagnosis and hospital type. By diagnosis, the most costly episodes were those involving cardiac arrest. Per-episode cost profiles were similar for stroke and cardiac arrest. For admissions for MI, CHF, and dysrhythmia, transplant hospitals had significantly higher costs, more high-cost hospitalizations, and longer LOSs without risk-adjusting for patient and hospital characteristics. Tables 3 and 4 demonstrate predictors associated with all-cause mortality and high-cost hospitalizations, respectively. Each table begins with an empty model and serially adds patient characteristics and hospital characteristics in subsequent models. For all-cause mortality in Table 3 , the quasi-likelihood information criterion (QIC) improved substantially with the addition of patient characteristics and then hospital characteristics to the model, indicating an improvement in model fitness. Transplant hospital status was not a significant predictor of mortality in the empty model, but with the addition of patient and hospital characteristics, it was found to be associated with 78%-99% higher odds of mortality compared with nontransplant hospitals. Other significant predictors of mortality included CVD burden, emergent/urgent hospitalization, and use of diagnostic but not therapeutic cardiac catheterization. Multiple factors were protective from mortality, including documentation of HTN and dyslipidemia, and therapeutic cardiac catheterization. Hospital structural characteristics were otherwise not predictors of mortality, but the presence of cardiac intensive care and more intense staffing were nearly significant and associated with improved survival.
With regard to predictors of high-cost hospitalization, Table 4 indicated that the sequential addition of patient and hospital characteristics to cost modeling improved model fitness from a QIC of 5521 to 3242. Transplant hospital status was initially a significant predictor of highcost hospitalization in model 1. After sequential risk adjustment (models 2 and 3), transplant hospital status was not associated with high-cost hospitalizations after adjusting for patient and other hospital characteristics. 
Original article | 1405
Factors associated with high cost were CVD burden and invasive CV procedures, including catheterization and surgical interventions. Protective factors from cost included emergent admission type and documentation of comorbid conditions. Hospital resources were not otherwise significant predictors of high-cost care, and hospitals with more Medicare discharges were less likely to have high-cost hospitalizations.
Discussion
This analysis clearly demonstrates the significant burden of CVD in the liver transplant population. CV events were responsible for over 4763 hospitalizations over 10 years. Mortality was 3.9% in these episodes. These hospitalizations were associated with significant costs, particularly when a CV procedure or surgery is required. There was demonstrable variation in mortality and costs across hospitals caring for liver transplant recipients in these critical situations, suggesting opportunities for improvement. Burden of CVD at admission was associated with higher mortality and costs of care. Transplant hospitals had nearly 2-fold higher risk-adjusted mortality in these episodes but were not associated with higher-cost hospitalizations after risk-adjusting for other hospital resources. Numerous studies have demonstrated significant CV morbidity and mortality after liver transplantation. (1, 2, 4, (39) (40) (41) (42) However, these outcomes vary across reports. For example, Albeldawi et al. demonstrated 13.5% incidence of a major CV event at 5 years after transplant, but a recent study by VanWagner et al. to develop a predictive model for posttransplant CV events demonstrated an incidence of 32%. (2, 42) The variation between hospitals suggests that posttransplant CV care can be improved. Until only recently, (43) there have been no specific guidelines for preventing *Total column percentages are not equal to total N due to missing administrative data in ~10% of the category. † Column percentages do not equal total N as categories are not mutually exclusive.
CV events in liver transplant patients (3, 39, 44) and limited guidelines for perioperative risk assessment. (45) (46) (47) Posttransplant care is frequently fragmented, with shifting responsibility between transplant hepatologists, gastroenterologists, surgeons, primary care physicians, and others. This decentralized practice pattern may inadvertently lead to less physician attention on addressing CV risk factors. Focus on CVD prevention and risk factor modification after transplant carries clinical benefits and can reduce health care cost expenditures. Previous research has focused on pretransplant evaluation as a focal point in reducing CV events. (45) (46) (47) (48) Pretransplant CV risk estimation has 2 goals. The first is to estimate the risk of perioperative morbidity and mortality in the setting of the liver transplant procedure itself, and the second is to establish a baseline for the longterm risk of CV events. These data suggest that longterm risk assessment during pretransplant evaluation alone is insufficient, and ongoing comprehensive CV risk assessments and preemptive treatment after transplant could reduce event rates. There is a clear need for revision of posttransplant CV care protocols and dissemination of best practices among care providers for treating this unique population. Why did liver transplant recipients with CV events fare worse in transplant hospitals versus nontransplant hospitals? We had hypothesized that transplant hospitals would have better outcomes due to resource intensity and established processes of transplant care delivery. However, transplant hospitals had significantly higher risk-adjusted mortality than nontransplant facilities. It is unclear specifically why transplant hospitals failed to rescue these patients, which warrants more specific analysis with richer clinical data. Interestingly, the documentation of CV risk factors at discharge was counterintuitively associated with lower mortality. This likely is related to hospital differences in coding and medical documentation, where hospitals aim to optimize episodic revenue by purposefully coding all medical diagnoses, particularly in nonprocedural Original article | 1407
Variation in cost of CV hospitalizations in liver transplant recipients. This figure represents the greater than 5-fold difference in mean hospital-specific episode costs for liver transplant recipients admitted for a primary CV diagnosis, including MI, stroke, CHF, dysrhythmia, malignant HTN, and cardiac arrest. The variation in these costs is attributable to multiple factors, including heterogeneity in diagnoses, differences in treatments, care efficiency, quality, as well as other differences within diagnosis groups. Each bin represents an individual hospital's mean costs over the study period. admissions. However, it is possible that hospitals where these comorbidities were strictly coded had better outcomes from better care processes. We believe that the overall findings are related to the following:
1. The selective referral of high-acuity patients to transplant facilities, whose clinical risk is incompletely captured by administrative data mechanisms. 2. The potential that transplant hospitals may be providing lower-quality CV care.
Higher patient acuity in transplant hospitals is a convenient explanation. Current measurement approaches for comorbidities in administrative health care are sometimes lacking. (49) However, quality of CV care in transplant hospitals should be carefully studied, including processes of CV care.
Costs of CVD care in the liver transplant population have heretofore not been described in the inpatient setting. Understanding predictors of high-cost CV care among liver transplant recipients is important in understanding the value of posttransplant care delivery. Transplant hospital status alone was not predictive of high-cost care after risk-adjusting for patient differences, procedure utilization, and facility resources. However, cost variation in CVD care in the general population is known to exist, (50) (51) (52) and some of the variation identified here is likely related to heterogeneity in presenting CV diagnosis at different hospitals. Intuitively, CV surgery was a significant predictor of high-cost care in this analysis. CV surgical care is resource-intense from a clinical standpoint and requires capacity, provider expertise, special technology, and personnel in a resource-rich hospital setting. Value of CV care delivery in the inpatient setting is a growing area of research and a concern for payers. (53, 54) As more liver transplant procedures are done, CV care delivery in this population will distinctly influence how we approach value in this population.
The goal of this analysis was to identify whether hospital resource intensity reduces the risk of mortality or costs once a CV event occurs in a liver transplant recipient. A limitation of the analysis is the absence of linkage of hospitalization records, rendering it impossible to identify when liver transplant procedures occurred relative to CV events, which would add further nuance to this evaluation. VanWagner et al. have identified high rates of CV events in the first year after transplant, which potentially affects our observations in transplant hospitals. (55, 56) Additionally, we were unable to identify the effect of processes of CV care and their contribution to the transplant hospital effect. Future studies should evaluate differences in processes of CV care that could affect care in all hospitals. Administrative data are useful to outline population trends and drive hypothesis generation. Unfortunately, these data often lack clinical context and specificity. Further research from clinical registries, multicenter analyses, and other administrative data may help link time from transplant to CV event and further outline strategies for reduction of event rates. Causal pathways are not likely to be ascertained from this analysis, which should be used for hypothesis generation.
Generalizations from models capturing the effects of groups of hospitalizations also cannot be applied to predictions of outcomes for a given individual hospitalization. This study has demonstrated the significant risk associated with CVD in the liver transplant population, and it has further identified transplant hospital status as an indicator of mortality and costly health care expenditures. This may be related to selective referral of certain patient phenotypes to transplant centers, which is not captured by current limits of risk adjustment. However, within transplant facilities, further study should focus on improving quality of CV care delivery among this selected group of patients. Nontransplant facilities may also improve care protocols by including transplant status in the early assessment of patients presenting with CV events. Ultimately, care improvements for these patients should also focus on avoiding wasteful care that adds little clinical value. These efforts may yield new clinical benefits for liver transplant patients, identify strategies to adjust care protocols, and inform discussions of value in post-liver transplant care delivery.
